Patents by Inventor Marlys Hammond

Marlys Hammond has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE
    Publication number: 20200095217
    Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Application
    Filed: October 17, 2019
    Publication date: March 26, 2020
    Inventors: Sarah E. DOWDELL, Hilary Schenck EIDAM, Mark ELBAN, Ryan Michael FOX, Marlys HAMMOND, Mark A. HILFIKER, Tram H. HOANG, Lara KALLANDER, Brian Griffin LAWHORN, Sharada MANNS, Joanne PHILP, David G. WASHBURN, Guosen YE
  • Hydroxy formamide derivatives and their use
    Patent number: 10450288
    Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Sarah E. Dowdell, Hilary Schenck Eidam, Mark Elban, Ryan Michael Fox, Marlys Hammond, Mark A. Hilfiker, Tram H. Hoang, Lara Kallander, Brian Griffin Lawhorn, Sharada Manns, Joanne Philp, David G. Washburn, Guosen Ye
  • HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE
    Publication number: 20160340328
    Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Application
    Filed: January 9, 2015
    Publication date: November 24, 2016
    Inventors: Sarah E. DOWDELL, Hilary Schenck EIDAM, Mark ELBAN, Ryan Michael FOX, Marlys HAMMOND, Mark A. HILFIKER, Tram H. HOANG, Lara KALLANDER, Brian Griffin LAWHORN, Sharada MANNS, Joanne PHILP, David G. WASHBURN, Guosen YE
  • TRPV4 antagonists
    Patent number: 9487507
    Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: November 8, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Carl Brooks, Mui Cheung, Hilary Schenck Eidam, Krista B. Goodman, Marlys Hammond, Mark A. Hilfiker, Jaclyn R. Patterson, Patrick Stoy, Guosen Ye
  • TRPV4 antagonists
    Patent number: 9187464
    Abstract: The present invention relates to spirocarbamate compounds of Formula (I) in which R1, (R2)Y, R3, R4, X and A have the meanings given in the specification. The invention further provides pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and relates to their use of these compounds as TRPV4 antagonists in treating or preventing conditions associated with TRPV4 imbalance.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: November 17, 2015
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Carl Brooks, Mui Cheung, Hilary Schenck Eidam, Krista B. Goodman, Marlys Hammond, Mark A. Hilfiker, Tram H. Hoang, Jaclyn R. Patterson, Patrick Stoy, Guosen Ye
  • TRPV4 antagonists
    Patent number: 8927585
    Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: January 6, 2015
    Assignee: GlaxoSmithKline Intellectual Property (NO.2) Limited
    Inventors: Carl Brooks, Mui Cheung, Krista B. Goodman, Marlys Hammond
  • TRPV4 ANTAGONISTS
    Publication number: 20140135369
    Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: June 15, 2012
    Publication date: May 15, 2014
    Applicant: GlaxoSmith Kline,LLC
    Inventors: Carl Brooks, Mui Cheung, Krista B. Goodman, Marlys Hammond
  • TRPV4 ANTAGONISTS
    Publication number: 20140121206
    Abstract: The present invention relates to spirocarbamate compounds of Formula (I) in which R1, (R2)Y, R3, R4, X and A have the meanings given in the specification. The invention further provides pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and relates to their use of these compounds as TRPV4 antagonists in treating or preventing conditions associated with TRPV4 imbalance.
    Type: Application
    Filed: June 15, 2012
    Publication date: May 1, 2014
    Applicant: GlaxoSmithKliine, LLC
    Inventors: Carl Brooks, Mui Cheung, Hilary Schenck Eidam, Krista B. Goodman, Marlys Hammond, Mark A. Hilfiker, Tram H. Hoang, Jaclyn R. Patterson, Patrick Stoy, Guosen Ye
  • TRPV4 ANTAGONISTS
    Publication number: 20140113916
    Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: June 15, 2012
    Publication date: April 24, 2014
    Applicant: GlaxoSmithKLine, LLC
    Inventors: Carl Brooks, Mui Cheung, Hilary Schenck Eidam, Krista B. Goodman, Marlys Hammond, Mark A. Hilfiker, Jaclyn R. Patterson, Patrick Stoy, Guosen Ye
  • 1H-Pyrrolo[2,3-B]Pyridines
    Publication number: 20120238588
    Abstract: Derivatives of pyrrolo[2,3-b]pyridine which are useful as SGK-1 kinase inhibitors are described herein. The invention described herein also describes pharmaceutical compositions containing derivatives of pyrrolo[2,3-b]pyridine and methods of using pyrrolo[2,3-b]pyridine derivatives and pharmaceutical compositions thereof in the treatment of diseases mediated by SGK-1.
    Type: Application
    Filed: March 27, 2012
    Publication date: September 20, 2012
    Inventors: James S. Frazee, Marlys Hammond, Sharada Manns, Scott Kevin Thompson, David G. Washburn, Kazuya Kano, Hiroko Nakamura
  • Renin Inhibitors and Methods of Use Thereof
    Publication number: 20110160300
    Abstract: Disclosed are aspartic protease inhibitors represented by the following Formula: wherein R1, R2, R3, R4, R5, R6, R7a, R7b and n are as defined herein, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods for treating an aspartic protease mediated disorder using the same.
    Type: Application
    Filed: June 18, 2009
    Publication date: June 30, 2011
    Inventors: Marlys Hammond, Patrick Stoy
  • PROCESS FOR THE PREPARATION OF RENIN INHIBITORS
    Publication number: 20100311989
    Abstract: Disclosed is a process for the preparation of tetrahydropyran-di-amine represented by Structural Formula (I): wherein R1 is H or alkyl and E is H or an amine protecting group.
    Type: Application
    Filed: September 17, 2008
    Publication date: December 9, 2010
    Inventors: Marlys Hammond, Patrick Stoy, Scott K. Thompson
  • PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS
    Publication number: 20100210706
    Abstract: The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a combination thereof, wherein R1, R2, and X are as defined herein. Compounds of the present invention are useful as progesterone receptor modulators.
    Type: Application
    Filed: August 7, 2007
    Publication date: August 19, 2010
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: David G. Washburn, Scott Kevin Thompson, Marlys Hammond, James S. Frazee, Tram H. Hoang, Latisha C. Johnson
  • 1H-Pyrrolo[2,3-B]Pyridnes
    Publication number: 20090233955
    Abstract: Derivatives of pyrrolo[2,3-b]pyridine which are useful as SGK-1 kinase inhibitors are described herein. The invention described herein also describes pharmaceutical compositions containing derivatives of pyrrolo[2,3-b]pyridine and methods of using pyrrolo[2,3-b]pyridine derivatives and pharmaceutical compositions thereof in the treatment of diseases mediated by SGK-1.
    Type: Application
    Filed: December 8, 2005
    Publication date: September 17, 2009
    Inventors: James S. Frazee, Marlys Hammond, Sharada Manns, Scott Kevin Thompson, David G. Washburn, Kazuya Kano, Hiroko Nakamura
  • Cyanoarylamines
    Publication number: 20080194536
    Abstract: The present invention relates to a compound represented by the following formula: (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or a combination thereof, wherein Ro, R1, R1?, R2, R2?, R3 and n are defined herein. The present invention further relates to a method of treating a patient from endometreosis or uterine fibroids.
    Type: Application
    Filed: April 14, 2006
    Publication date: August 14, 2008
    Inventors: Marlys Hammond, David G. Jones, Istvan Kaldor, Lara S. Kallander, Xi Lang, Scott Kevin Thompson, Philip Stewart Turnbull, David G. Washburn
  • Tetraazabenzo[e]azulene derivatives and analogs thereof
    Patent number: 7358242
    Abstract: This invention relates to CCK-A agonists of Formula (I) wherein R1-R4, A, B, X, D, E and G are as defined in the specification, as well as, among other things, pharmaceutical compositions containing the compounds and methods of use of the compounds and compositions. The compounds are useful in treating diabetes.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: April 15, 2008
    Assignee: Pfizer Inc.
    Inventors: Richard L. Elliott, Kimberly O. Cameron, Marlys Hammond
  • CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
    Publication number: 20070275964
    Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
    Type: Application
    Filed: July 11, 2007
    Publication date: November 29, 2007
    Inventors: David Griffith, Marlys Hammond
  • TETRAAZABENZO[E]AZULENE DERIVATIVES AND ANALOGS THEREOF
    Publication number: 20070265193
    Abstract: This invention relates to CCK-A agonists of Formula (I) wherein R1-R4, A, B, X, D, E and G are as defined in the specification, as well as, among other things, pharmaceutical compositions containing the compounds and methods of use of the compounds and compositions. The compounds are useful in treating diabetes.
    Type: Application
    Filed: July 20, 2007
    Publication date: November 15, 2007
    Inventors: Richard Elliott, Kimberly Cameron, Marlys Hammond
  • PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF
    Publication number: 20070254935
    Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment diseases, conditions and/or disorders modulated by cannabinoid receptor antagonists in animals are described herein.
    Type: Application
    Filed: June 21, 2007
    Publication date: November 1, 2007
    Inventors: Robert Dow, Marlys Hammond
  • Cannabinoid receptor ligands and uses thereof
    Patent number: 7268133
    Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: September 11, 2007
    Assignee: Pfizer, Inc. Patent Department
    Inventors: David A. Griffith, Marlys Hammond